| Category Name | Content |
| Name | Peptide Sermorelin – Injectable & Oral |
| Uses | Peptide therapy used to stimulate the release of growth hormone (GH) from the pituitary gland, promoting muscle growth, fat metabolism, improved sleep, and anti-aging benefits. |
| Route Of Administration | Subcutaneous injection or oral troche. |
| Frequency Of Use | Typically administered daily at bedtime for optimal GH release. |
| Concentration(s) | Common formulations: - **Injectable:** 3 mg/mL, 6 mg/mL, 9 mg/mL reconstituted solution - **Oral Troche:** 0.5-2 mg per troche |
| Maximum Dosage (Day, Wk) | Recommended maximum dose: - **Injectable:** 200-500 mcg subcutaneous per dose, daily - **Oral:** 0.5-2 mg per troche, daily |
| Contraindications | Pregnancy, breastfeeding, active cancer, history of pituitary tumors, uncontrolled diabetes, or hypersensitivity to Sermorelin. |
| Possible Side Effects | Mild injection site reactions, flushing, dizziness, headache, nausea, increased appetite, water retention, or rare allergic reactions. |
| Compatibility With Other Treatments/Drugs | Avoid concurrent use with exogenous growth hormone (GH) therapy. Safe to combine with other peptides like Ipamorelin and CJC-1295. |
| Allergies | Assess for hypersensitivity to Sermorelin or any excipients in injectable or oral formulations. |
| Administration Time | Injectable: Administer subcutaneously at bedtime for optimal GH secretion. Oral: Dissolve troche under the tongue at bedtime. |
| Dosing/Settings | Standard dosing protocol: - **Injectable:** 200-500 mcg subcutaneously per dose, daily - **Oral:** 0.5-2 mg per troche, daily |
| Test Spot Requirement | Not required; however, first-time users should start with the lowest effective dose to assess tolerance. |
| Pre-Treatment Guidelines | - Avoid eating 2 hours before and after administration to enhance GH response. - Store injectable Sermorelin in the refrigerator after reconstitution. - Monitor IGF-1 levels periodically to assess effectiveness. |
| Provider Clearance Guidelines | - Ensure the patient meets all clearance criteria before treatment. - If the patient has a history of cancer, consult an endocrinologist before prescribing. - Document all clearance decisions in the patient’s medical record. |
| Pre-Treatment Screening Workflow | - Does the patient have a history of cancer? (If YES, contraindicated) - Is the patient currently pregnant or breastfeeding? (If YES, contraindicated) - Does the patient have uncontrolled diabetes? (If YES, avoid treatment) - Has the patient had recent pituitary dysfunction? (If YES, refer to endocrinology) |
| What To Do If Adverse Reaction Occurs | - **Injection site reactions**: Apply a cool compress and rotate injection sites. - **Headache or dizziness**: Lower dosage and monitor hydration. - **Nausea**: Advise taking on an empty stomach and spacing out administration. - **Severe allergic reaction (rare)**: Discontinue immediately and provide appropriate medical care. |
| Clinic Implementation Guidelines | - Confirm all consents are signed before treatment. - Educate the patient on proper injection technique or oral troche usage. - Store injectable Sermorelin per compounding pharmacy recommendations. - Schedule follow-up to assess efficacy and tolerance. |
| Photographic Documentation Protocol | Not required for Sermorelin administration. |
| Post-Treatment Care | - Monitor IGF-1 levels periodically to track response. - Maintain a record of patient symptoms and progress. - Adjust dosing as needed based on response and tolerability. |
| Additional Documentation Requirements | - Signed informed consent detailing risks, benefits, and expected outcomes. - Treatment log including prescribed dosage and patient response. - Post-treatment care instructions provided and documented. |